# Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC)

> **NCT00464295** · PHASE2 · COMPLETED · sponsor: **Aga Khan University** · enrollment: 15 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Capecitabine in HCC

## Key facts

- **NCT ID:** NCT00464295
- **Lead sponsor:** Aga Khan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2007-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00464295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00464295, "Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00464295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*